CO6430431A2 - Inhibidores del virus de la hepatitis c - Google Patents
Inhibidores del virus de la hepatitis cInfo
- Publication number
- CO6430431A2 CO6430431A2 CO11123611A CO11123611A CO6430431A2 CO 6430431 A2 CO6430431 A2 CO 6430431A2 CO 11123611 A CO11123611 A CO 11123611A CO 11123611 A CO11123611 A CO 11123611A CO 6430431 A2 CO6430431 A2 CO 6430431A2
- Authority
- CO
- Colombia
- Prior art keywords
- hepatitis
- novel compounds
- hcv
- virus inhibitors
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente divulgación se refiere a compuestos novedosos de la Fórmula (I) tal como se definen en la memoria descriptiva y a las composiciones que comprenden dichos compuestos novedosos. Estos compuestos son agentes antivirales útiles, especialmente para inhibir la función de la proteína NS5A codificada por el virus de la hepatitis C (VHC). Por lo tanto, la divulgación también se refiere a un procedimiento de tratamiento de enfermedades o afecciones relacionadas con VHC mediante el uso de estos compuestos novedosos o de una composición que comprende dichos compuestos novedosos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16453109P | 2009-03-30 | 2009-03-30 | |
US12/729,940 US8796466B2 (en) | 2009-03-30 | 2010-03-23 | Hepatitis C virus inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6430431A2 true CO6430431A2 (es) | 2012-04-30 |
Family
ID=42320079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO11123611A CO6430431A2 (es) | 2009-03-30 | 2011-09-21 | Inhibidores del virus de la hepatitis c |
Country Status (19)
Country | Link |
---|---|
US (1) | US8796466B2 (es) |
EP (1) | EP2414350B1 (es) |
JP (1) | JP5612660B2 (es) |
KR (1) | KR20120034603A (es) |
CN (1) | CN102448956B (es) |
AR (1) | AR076002A1 (es) |
AU (1) | AU2010234970A1 (es) |
BR (1) | BRPI1013393A2 (es) |
CA (1) | CA2757269A1 (es) |
CL (1) | CL2011002426A1 (es) |
CO (1) | CO6430431A2 (es) |
EA (1) | EA022384B1 (es) |
IL (1) | IL215055A0 (es) |
MX (1) | MX2011009948A (es) |
NZ (1) | NZ595168A (es) |
PE (1) | PE20120546A1 (es) |
SG (1) | SG174521A1 (es) |
WO (1) | WO2010117635A1 (es) |
ZA (1) | ZA201106795B (es) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0922366B8 (pt) | 2008-12-03 | 2021-05-25 | Presidio Pharmaceuticals Inc | composto, composição farmacêutica e uso de um composto |
SG172352A1 (en) | 2008-12-23 | 2011-07-28 | Abbott Lab | Anti-viral compounds |
JP2012513410A (ja) | 2008-12-23 | 2012-06-14 | アボット・ラボラトリーズ | 抗ウイルス化合物 |
US8314135B2 (en) | 2009-02-09 | 2012-11-20 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole antivirals |
US8188132B2 (en) | 2009-02-17 | 2012-05-29 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
US8242156B2 (en) | 2009-02-17 | 2012-08-14 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8673954B2 (en) | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US8101643B2 (en) | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US9765087B2 (en) | 2009-02-27 | 2017-09-19 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
RU2541571C2 (ru) * | 2009-04-15 | 2015-02-20 | Эббви Инк. | Противовирусные соединения |
CA2759142A1 (en) * | 2009-04-24 | 2010-10-28 | Tibotec Pharmaceuticals | Diaryl ethers |
EA027493B1 (ru) | 2009-05-13 | 2017-07-31 | Джилид Фармассет Ллс | Промежуточные соединения для получения противовирусного соединения |
US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
NZ591973A (en) * | 2009-06-11 | 2013-03-28 | Abbott Lab | Anti-viral compounds to treat hcv infection |
US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
US8221737B2 (en) | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8609648B2 (en) | 2009-07-02 | 2013-12-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
AU2010274001A1 (en) | 2009-07-16 | 2012-02-23 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of Flavivirus infections |
KR20120076343A (ko) | 2009-09-04 | 2012-07-09 | 글락소스미스클라인 엘엘씨 | 화합물 |
US8927709B2 (en) | 2009-09-11 | 2015-01-06 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US9156818B2 (en) | 2009-09-11 | 2015-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8703938B2 (en) | 2009-09-11 | 2014-04-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8759332B2 (en) | 2009-09-11 | 2014-06-24 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8815928B2 (en) | 2009-09-11 | 2014-08-26 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8822700B2 (en) | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
WO2011081918A1 (en) | 2009-12-14 | 2011-07-07 | Enanta Pharmaceuticals, Inc | Hepatitis c virus inhibitors |
US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
JP2013518060A (ja) | 2010-01-25 | 2013-05-20 | エナンタ ファーマシューティカルズ インコーポレイテッド | C型肝炎ウイルス阻害剤 |
US8623814B2 (en) | 2010-02-23 | 2014-01-07 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
US8178531B2 (en) | 2010-02-23 | 2012-05-15 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
EP2542074A4 (en) | 2010-03-04 | 2014-05-14 | Enanta Pharm Inc | PHARMACEUTICAL COMBINATION ACTIVE AGENTS AS HCV REPLICATION INHIBITORS |
AU2011232331A1 (en) | 2010-03-24 | 2012-10-11 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of Flavivirus infections |
WO2011127350A1 (en) | 2010-04-09 | 2011-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
US20130296311A1 (en) * | 2010-05-28 | 2013-11-07 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
US8778938B2 (en) | 2010-06-04 | 2014-07-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
MX2012014918A (es) | 2010-06-28 | 2013-04-08 | Vertex Pharma | Compuestos y metodos para tratamiento o prevencion de infecciones por flavivirus. |
WO2012006070A1 (en) | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
EP2585448A1 (en) | 2010-06-28 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
US8697704B2 (en) | 2010-08-12 | 2014-04-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
AU2011292040A1 (en) | 2010-08-17 | 2013-03-07 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of Flaviviridae viral infections |
CN103249730A (zh) * | 2010-09-24 | 2013-08-14 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
AU2014203655B2 (en) * | 2010-10-13 | 2016-07-07 | Abbvie Ireland Unlimited Company | Anti-viral compounds |
RU2452735C1 (ru) | 2010-11-30 | 2012-06-10 | Александр Васильевич Иващенко | Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения |
MX2013006828A (es) * | 2010-12-16 | 2014-10-14 | Abbvie Inc | Compuestos antivirales. |
WO2012083170A1 (en) * | 2010-12-16 | 2012-06-21 | Abbott Laboratories | Anti-viral compounds |
US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9546160B2 (en) * | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
JP5669984B2 (ja) | 2011-05-18 | 2015-02-18 | エナンタ ファーマシューティカルズ インコーポレイテッド | 5−アザスピロ[2.4]ヘプタン−6−カルボン酸およびその誘導体の製造方法 |
CA2841095A1 (en) * | 2011-07-09 | 2013-01-17 | Sunshine Lake Pharma Co., Ltd. | Spiro compounds as hepatitis c virus inhibitors |
WO2013016499A1 (en) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Methods for preparation of thiophene compounds |
WO2013016492A1 (en) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Thiophene compounds |
WO2013021344A1 (en) | 2011-08-08 | 2013-02-14 | Lupin Limited | Imidazole derivatives as antiviral agents |
NZ623396A (en) | 2011-09-16 | 2016-07-29 | Gilead Pharmasset Llc | Methods for treating hcv |
WO2013067267A1 (en) | 2011-11-03 | 2013-05-10 | Theravance, Inc. | Rod -like hepatitis c virus inhibitors containing the fragement {2- [4- (bi phenyl - 4 - yl) - 1h - imidazo - 2 - yl] pyrrolidine - 1 - carbonlymethyl} amine |
CA2858659A1 (en) | 2011-12-28 | 2013-07-04 | Janssen R&D Ireland | Hetero-bicyclic derivatives as hcv inhibitors |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
NZ630805A (en) | 2012-03-22 | 2016-01-29 | Alios Biopharma Inc | Pharmaceutical combinations comprising a thionucleotide analog |
CA2869640C (en) | 2012-04-25 | 2018-03-20 | Theravance Biopharma R&D Ip, Llc | Piperazine-piperidine compounds as hepatitis c virus inhibitors |
LT2950786T (lt) | 2013-01-31 | 2020-03-10 | Gilead Pharmasset Llc | Dviejų antivirusinių junginių preparatų kompozicija |
RU2507201C1 (ru) | 2013-02-07 | 2014-02-20 | Александр Васильевич Иващенко | Алкил [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-метоксикарбониламино-3-метил-бутирил)-пирролидин-2-ил]-3н-имидазол-4-ил}-бута-1,3-диинил)-фенил]-1н-имидазол-2-ил}-пирролидин-1-карбонил)-2-метил-пропил]-карбамат нафталин-1,5-дисульфонат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний |
TW201526899A (zh) | 2013-02-28 | 2015-07-16 | Alios Biopharma Inc | 醫藥組成物 |
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
CN104230946B (zh) * | 2013-06-06 | 2017-03-08 | 爱博新药研发(上海)有限公司 | 抑制丙肝病毒的化合物、药物组合物及其应用 |
US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
EP3021845A1 (en) | 2013-07-17 | 2016-05-25 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of hcv |
MX2016002185A (es) | 2013-08-27 | 2016-06-06 | Gilead Pharmasset Llc | Formulacion combinada de dos compuestos antivirales. |
CN104628584B (zh) * | 2013-11-08 | 2017-03-08 | 广州朗圣药业有限公司 | 一种适合工业化的高纯度达泊西汀的制备方法 |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN105294713A (zh) * | 2015-10-09 | 2016-02-03 | 重庆康施恩化工有限公司 | Velpatasvir中间体及其制备方法 |
WO2017076201A1 (zh) * | 2015-11-06 | 2017-05-11 | 江苏豪森药业集团有限公司 | Hcv抑制剂、其制备方法与应用 |
CN108164486B (zh) * | 2018-03-06 | 2021-02-12 | 徐州医科大学 | 一种醚类化合物的绿色高效合成方法 |
US11401242B2 (en) * | 2018-09-19 | 2022-08-02 | Corteva Agriscience Llc | Preparation of halogen analogs of picloram |
CN109456375B (zh) * | 2018-12-11 | 2019-10-22 | 枣庄学院 | 一种抑制丙肝病毒的含单糖基杂环类化合物及制备方法 |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5654451B1 (en) | 1993-01-14 | 2000-02-22 | Magainin Pharma | Amino acids and peptides having modified c-terminals and modified n-terminals |
CA2153987A1 (en) | 1993-01-14 | 1994-07-21 | U. Prasad Kari | Amino acids and peptides having modified terminals |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
AU2003249977A1 (en) | 2002-07-05 | 2004-01-23 | Axxima Pharmaceuticals Ag | Imidazole compounds for the treatment of hepatitis c virus infections |
US20050069522A1 (en) | 2002-08-12 | 2005-03-31 | Richard Colonno | Combination pharmaceutical agents as inhibitors of HCV replication |
US7420079B2 (en) | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2006022442A1 (ja) | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
GB2438802A (en) | 2005-02-28 | 2007-12-05 | Univ Rockefeller | Structure of the hepatitis C virus NS5A protein |
US8143288B2 (en) | 2005-06-06 | 2012-03-27 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
BRPI0615934A2 (pt) | 2005-09-16 | 2011-05-31 | Arrow Therapeutics Ltd | composto ou um sal farmaceuticamente aceitável do mesmo, uso de um derivado de bifenila, composição farmacêutica, e, produto |
WO2007058384A1 (en) | 2005-11-17 | 2007-05-24 | Osaka University | Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same |
US7915411B2 (en) | 2005-12-21 | 2011-03-29 | Abbott Laboratories | Anti-viral compounds |
ES2378473T3 (es) | 2005-12-21 | 2012-04-12 | Abbott Laboratories | Compuestos antivirales |
SG133452A1 (en) | 2005-12-30 | 2007-07-30 | Novartis Ag | Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases |
MX2008014990A (es) | 2006-05-30 | 2008-12-09 | Arrow Therapeutics Ltd | Derivados de bifenilo y su uso en el tratamiento de hepatitis c. |
JP2010504281A (ja) | 2006-07-27 | 2010-02-12 | エミスフェアー・テクノロジーズ・インク | アリールスルファニル化合物、および活性薬剤を送達するための組成物 |
US20100158862A1 (en) | 2006-08-11 | 2010-06-24 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2097405A2 (en) | 2006-11-21 | 2009-09-09 | Smithkline Beecham Corporation | Anti-viral compounds |
WO2008133753A2 (en) | 2006-12-20 | 2008-11-06 | Abbott Laboratories | Anti-viral compounds |
US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8629171B2 (en) | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
US7728027B2 (en) | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
US8491023B2 (en) * | 2007-09-04 | 2013-07-23 | Schlage Lock Company Llc | Door lock assembly |
CN101389072B (zh) * | 2007-09-12 | 2011-05-25 | 中兴通讯股份有限公司 | 高速下行共享信道的传输信道时间调整方法 |
BRPI0907733A2 (pt) | 2008-02-12 | 2015-07-14 | Bristol Myers Squibb Co | Inibidores do vírus da hepatite c |
PL2250163T3 (pl) | 2008-02-12 | 2012-10-31 | Bristol Myers Squibb Co | Inhibitory wirusa zapalenia wątroby typu C |
US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
ES2391600T3 (es) | 2008-02-13 | 2012-11-28 | Bristol-Myers Squibb Company | Imidazoli bifenil imidazoles como inhibidores del virus de la hepatitis C |
US7906655B2 (en) | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8383094B2 (en) | 2008-10-01 | 2013-02-26 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2010062821A1 (en) | 2008-11-28 | 2010-06-03 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
BRPI0922366B8 (pt) | 2008-12-03 | 2021-05-25 | Presidio Pharmaceuticals Inc | composto, composição farmacêutica e uso de um composto |
CN102300462B (zh) * | 2008-12-03 | 2015-01-28 | 普雷西迪奥制药公司 | Hcv ns5a的抑制剂 |
SG172352A1 (en) | 2008-12-23 | 2011-07-28 | Abbott Lab | Anti-viral compounds |
EP2393359A4 (en) | 2009-02-09 | 2012-10-03 | Enanta Pharm Inc | COMPOUND DIBENZIMIDAZOLE DERIVATIVES |
WO2010096462A1 (en) | 2009-02-17 | 2010-08-26 | Enanta Pharmaceuticals, Inc | Linked diimidazole derivatives |
US8420686B2 (en) * | 2009-02-17 | 2013-04-16 | Enanta Pharmaceuticals, Inc. | Linked diimidazole antivirals |
TWI438200B (zh) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
WO2010094977A1 (en) | 2009-02-23 | 2010-08-26 | Arrow Therapeutics Limited | Novel biphenyl compounds useful for the treatment of hepatitis c |
EP2398474A4 (en) | 2009-02-23 | 2012-12-05 | Presidio Pharmaceuticals Inc | HCV NS5A SHEMMER |
SG174146A1 (en) | 2009-02-27 | 2011-10-28 | Enanta Pharm Inc | Hepatitis c virus inhibitors |
AU2010229833B2 (en) | 2009-03-27 | 2014-03-13 | Merck Sharp & Dohme Llc | Inhibitors of hepatitis C virus replication |
PE20120773A1 (es) | 2009-03-27 | 2012-07-19 | Presidio Pharmaceuticals Inc | Anillos triciclicos fusionados sustituidos como inhibidores del virus de hepatitis c |
CA2756255A1 (en) | 2009-03-27 | 2010-09-30 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic hcv inhibitors |
TWI476190B (zh) | 2009-03-30 | 2015-03-11 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
RU2541571C2 (ru) | 2009-04-15 | 2015-02-20 | Эббви Инк. | Противовирусные соединения |
CA2759142A1 (en) | 2009-04-24 | 2010-10-28 | Tibotec Pharmaceuticals | Diaryl ethers |
EP2430015B1 (en) | 2009-05-12 | 2015-06-17 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds useful for the treatment of viral diseases |
EA027493B1 (ru) | 2009-05-13 | 2017-07-31 | Джилид Фармассет Ллс | Промежуточные соединения для получения противовирусного соединения |
JP2012528195A (ja) | 2009-05-29 | 2012-11-12 | メルク・シャープ・アンド・ドーム・コーポレーション | C型肝炎などの疾患を処置するための3つの結合アリール部分で構成された抗菌性化合物 |
US8772505B2 (en) | 2009-05-29 | 2014-07-08 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis C |
US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
NZ591973A (en) | 2009-06-11 | 2013-03-28 | Abbott Lab | Anti-viral compounds to treat hcv infection |
WO2010148006A1 (en) | 2009-06-16 | 2010-12-23 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
WO2011004276A1 (en) | 2009-07-06 | 2011-01-13 | Pfizer Limited | Hepatitis c virus inhibitors |
AU2010274001A1 (en) | 2009-07-16 | 2012-02-23 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of Flavivirus infections |
EP2462136A1 (en) | 2009-08-07 | 2012-06-13 | Janssen R&D Ireland | Phenyl ethynyl derivatives as hepatitis c virus inhibitors |
BR112012002662A2 (pt) | 2009-08-07 | 2016-03-22 | Tibotec Pharm Ltd | derivados de bis-benzimidazol |
BR112012004969A2 (pt) | 2009-09-03 | 2019-09-24 | Tibotec Pharm Ltd | derivados de bis-benzimidazol |
KR20120076343A (ko) | 2009-09-04 | 2012-07-09 | 글락소스미스클라인 엘엘씨 | 화합물 |
US9156818B2 (en) | 2009-09-11 | 2015-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
WO2011031934A1 (en) | 2009-09-11 | 2011-03-17 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
US8415374B2 (en) | 2009-10-12 | 2013-04-09 | Bristol-Myers Squibb Company | Combinations of hepatitis C virus inhibitors |
WO2011050146A1 (en) | 2009-10-23 | 2011-04-28 | Glaxosmithkline Llc | Chemical compounds |
UA108211C2 (uk) | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
WO2011066241A1 (en) | 2009-11-25 | 2011-06-03 | Schering Corporation | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
MY179840A (en) | 2009-12-04 | 2020-11-18 | National Health Res Inst | Proline derivatives |
WO2011081918A1 (en) | 2009-12-14 | 2011-07-07 | Enanta Pharmaceuticals, Inc | Hepatitis c virus inhibitors |
US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2011075615A1 (en) | 2009-12-18 | 2011-06-23 | Idenix Pharmaceuticals, Inc. | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
US20110152246A1 (en) | 2009-12-18 | 2011-06-23 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
WO2011087740A1 (en) | 2009-12-22 | 2011-07-21 | Schering Corporation | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
EP2515902A1 (en) | 2009-12-24 | 2012-10-31 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2011091446A1 (en) | 2010-01-22 | 2011-07-28 | Glaxosmithkline Llc | Chemical compounds |
JP2013518060A (ja) | 2010-01-25 | 2013-05-20 | エナンタ ファーマシューティカルズ インコーポレイテッド | C型肝炎ウイルス阻害剤 |
WO2011091532A1 (en) | 2010-01-28 | 2011-08-04 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
-
2010
- 2010-03-23 US US12/729,940 patent/US8796466B2/en active Active
- 2010-03-24 PE PE2011001734A patent/PE20120546A1/es not_active Application Discontinuation
- 2010-03-24 WO PCT/US2010/028456 patent/WO2010117635A1/en active Application Filing
- 2010-03-24 CA CA2757269A patent/CA2757269A1/en not_active Abandoned
- 2010-03-24 SG SG2011068657A patent/SG174521A1/en unknown
- 2010-03-24 JP JP2012503512A patent/JP5612660B2/ja not_active Expired - Fee Related
- 2010-03-24 CN CN201080024916.0A patent/CN102448956B/zh not_active Expired - Fee Related
- 2010-03-24 NZ NZ595168A patent/NZ595168A/xx not_active IP Right Cessation
- 2010-03-24 AU AU2010234970A patent/AU2010234970A1/en not_active Abandoned
- 2010-03-24 KR KR1020117025611A patent/KR20120034603A/ko not_active Application Discontinuation
- 2010-03-24 EP EP10722818.1A patent/EP2414350B1/en not_active Not-in-force
- 2010-03-24 BR BRPI1013393A patent/BRPI1013393A2/pt active Search and Examination
- 2010-03-24 MX MX2011009948A patent/MX2011009948A/es active IP Right Grant
- 2010-03-24 EA EA201171152A patent/EA022384B1/ru not_active IP Right Cessation
- 2010-03-30 AR ARP100101038A patent/AR076002A1/es unknown
-
2011
- 2011-09-08 IL IL215055A patent/IL215055A0/en unknown
- 2011-09-16 ZA ZA2011/06795A patent/ZA201106795B/en unknown
- 2011-09-21 CO CO11123611A patent/CO6430431A2/es active IP Right Grant
- 2011-09-30 CL CL2011002426A patent/CL2011002426A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AR076002A1 (es) | 2011-05-11 |
AU2010234970A1 (en) | 2011-10-06 |
ZA201106795B (en) | 2013-02-27 |
NZ595168A (en) | 2013-05-31 |
SG174521A1 (en) | 2011-10-28 |
WO2010117635A1 (en) | 2010-10-14 |
EP2414350B1 (en) | 2014-11-12 |
CA2757269A1 (en) | 2010-10-14 |
KR20120034603A (ko) | 2012-04-12 |
CL2011002426A1 (es) | 2012-03-02 |
MX2011009948A (es) | 2011-10-06 |
CN102448956B (zh) | 2015-05-06 |
CN102448956A (zh) | 2012-05-09 |
US20110077280A1 (en) | 2011-03-31 |
PE20120546A1 (es) | 2012-05-21 |
BRPI1013393A2 (pt) | 2016-03-29 |
IL215055A0 (en) | 2011-11-30 |
US8796466B2 (en) | 2014-08-05 |
EA022384B1 (ru) | 2015-12-30 |
JP5612660B2 (ja) | 2014-10-22 |
EA201171152A1 (ru) | 2012-10-30 |
JP2012522053A (ja) | 2012-09-20 |
EP2414350A1 (en) | 2012-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6430431A2 (es) | Inhibidores del virus de la hepatitis c | |
CO6361922A2 (es) | Inhibidores del virus de la hepatitis c | |
PE20230684A1 (es) | Analogos de carba-nucleosidos sustituidos con 2'-fluoro como inhibidores de la arn polimerasa | |
CL2012001230A1 (es) | Compuestos derivados de biciclos, inhibidores de la proteina ns5a; composicion farmaceutica que los comprende; uso en el tratamiento de la hepatitis c. | |
MX2013002927A (es) | Inhibidores del virus de la hepatitis c. | |
HN2009000792A (es) | Inhibidores de la proteasa ns3 del hcv | |
ECSP088518A (es) | Nucleósidos antivirales | |
CL2013003171A1 (es) | Compuesto macrociclico derivado de prolina inhibidor de la proteasa serina ns3; su composicion farmaceutica; y su uso en el tratamiento de una infeccion viral, en particular una infeccion causada por el virus de la hepatitis c (vhc). | |
GT200600317A (es) | Inhibidores de la proteasa ns3 del vhc | |
CO6190510A2 (es) | Inhibidores del virus de la hepatitis c | |
EA201270555A1 (ru) | Комбинации ингибиторов вируса гепатита с | |
CO6561788A2 (es) | Inhibidores del virus de la hepatitis c | |
NI201100172A (es) | Inhibidores de la replicación del virus de la hepatitis c | |
CO6400192A2 (es) | Inhibidores del virus de la hepatitis c | |
ATE469155T1 (de) | Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer | |
ATE483712T1 (de) | Hcv-ns5b-inhibitoren | |
ECSP10010210A (es) | Compuestos nucleósidos antivirales | |
MX2010002904A (es) | N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv). | |
CO6761335A2 (es) | Inhibidores del virus de la hepatitis c | |
EA201390155A1 (ru) | Комбинации ингибиторов вируса гепатита с | |
DK2209789T3 (da) | Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere | |
UY34066A (es) | Inhibidores del virus de la hepatitis c | |
UY31849A (es) | Nuevos compuestos como inhibidores de pde4 | |
UY32721A (es) | Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados | |
SV2007002309A (es) | Compuestos 5-nitro-nucleosidos para tratar infecciones virales |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |